Previous 10 |
Pfenex ( PFNX +2.6% ) expands its agreement with Alvogen Ltd. to develop and commercialize PF708, a biosimilar to Eli Lilly's ( LLY +0.8% ) osteoporosis med FORTEO (teriparatide), to the EU, certain countries in Middle East and North Africa (MENA) and rest-of-world (ROW) territori...
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Alvogen Ltd. today announced entering into agreements expanding their collaboration to develop and commercialize Pfenex’s lead product candidate, PF708, a proprietary teriparatide therapeutic equivalen...
SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that Ee...
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today announced that it will re...
The FDA has accepted for review Pfenex's (NYSEMKT: PFNX ) NDA for PF708, a Forteo therapeutic equivalent in the treatment of osteoporosis. More news on: Pfenex, Healthcare stocks news, Read more ...
SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the 505(b)(2) New Drug Application (NDA) for the Company’s lead product candidate, PF708, a Forteo® therapeutic...
The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde , founder, and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to it...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...